TABLE 4.
Sensitivity of Incremental Cost per Month of OS
| Parameter | Everolimus vs. Cabozantinib, $ | Everolimus vs. Nivolumab, $ | Everolimus vs. Axitinib, $ | |||
|---|---|---|---|---|---|---|
| Low Value | High Value | Low Value | High Value | Low Value | High Value | |
| Base case | 48,773 | 24,214 | Everolimus has lower costs | and greater efficacy | ||
| Everolimus PFS, bounds of 95% CI | 44,255 | 52,304 | 20,261 | 27,304 | Everolimus has lower costs and greater efficacy | Everolimus has lower costs and greater efficacy |
| Comparator PFS, bounds of 95% CI | 44,529 | 42,073 | 20,946 | 27,482 | Everolimus has lower costs and greater efficacy | Everolimus has lower costs and greater efficacy |
| Everolimus OS, bounds of 95% CI | 33,310 | 154,748 | 18,226 | 53,933 | 100,034 | Everolimus has lower costs and greater efficacy |
| Comparator OS, bounds of 95% CI | 81,601 | 34,196 | Everolimus has lower costs and greater efficacy | 21,523 | Everolimus has lower costs and greater efficacy | 53,543 |
| Everolimus WAC price, ±25% | 70,900 | 26,646 | 43,575 | 4,853 | Everolimus has lower costs and greater efficacy | Everolimus has lower costs and greater efficacy |
| Comparator WAC price, ±25% | 34,564 | 62,981 | 483 | 47,945 | 2,947 | Everolimus has lower costs and greater efficacy |
| AWP prices | 59,488 | – | 27,710 | – | Everolimus has lower costs and greater efficacy | – |
| Everolimus treatment duration, ±25% | 72,911 | 40,727 | 45,335 | 17,174 | Everolimus has lower costs and greater efficacy | Everolimus has lower costs and greater efficacy |
| Comparator treatment duration, ±25% | 12,106 | 48,773 | 16,741 | 24,214 | Everolimus has lower costs and greater efficacy | Everolimus has lower costs and greater efficacy |
| Other postprogression costs, ±25% | 48,852 | 48,694 | 24,179 | 24,249 | Everolimus has lower costs and greater efficacy | Everolimus has lower costs and greater efficacy |
| Duration of third-line treatment, ±50% or ±25% | 49,951 | 48,773 | 19,856 | 24,214 | Everolimus has lower costs and greater efficacy | Everolimus has lower costs and greater efficacy |
| Cost of adverse events, ±25% | 48,737 | 48,808 | 24,741 | 23,687 | Everolimus has lower costs and greater efficacy | Everolimus has lower costs and greater efficacy |
Note: All costs are in 2016 U.S. dollars.
AWP = average wholesale price; CI = confidence interval; OS = overall survival; PFS = progression-free survival; WAC = wholesale acquisition cost.